Fredun Pharmaceuticals has informed that the Board of Directors of Fredun Pharmaceuticals (hereinafter referred to as the Company), at their Meeting held on Wednesday, 19th July, 2023 had considered and approved the following items: In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2023 along with the Limited Review Report as issued by RH Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; Appointment of Niharika Agarwal (DIN: 10192397) as an Additional Director of the Company in the category of Independent Director for a term of 5 years with effective 19th July, 2023, subject to the approval of members at the ensuing Annual General Meeting of the Company. A brief profile of Niharika Agarwal is enclosed as Annexure A; Resignation of Chandrakant Shah (DIN: 02843653) as Independent Director with effect from 19th July, 2023. In furtherance to the intimation filed by the Company dated 29th June, 2023 the Trading Window for trading in securities of the Company by insiders which was dosed on Saturday, 01 st July, 2023 and shall be opened after 48 hours from the declaration of Financial Results.
The above information is a part of company’s filings submitted to BSE.